查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2148809

心臟衰竭藥物市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026-2034年預測。

Heart Failure Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 204 Pages | 商品交期: 2-3個工作天內

價格

心臟衰竭藥物市場的成長要素

2025年全球心臟衰竭治療市場規模為117.9億美元。預計該市場將從2026年的134.3億美元成長到2034年的384.6億美元，在2026年至2034年的預測期內，複合年成長率（CAGR）為14.06%。 2025年，北美在全球心臟衰竭治療市場中佔據領先地位，市佔率達43.34%，市場規模約51.1億美元。

全球心臟衰竭治療市場涵蓋用於治療各種適應症的慢性及急性心臟衰竭的處方藥。市場成長的促進因素包括：全球心臟衰竭衰竭盛行率上升、人口老化、糖尿病和高血壓等心血管代謝疾病的增加、指南指導的藥物治療（GDMT）的日益普及以及對高階品牌藥物需求的不斷成長。

該市場包括SGLT2抑制劑、ARNI、 BETA阻斷劑、ACE抑制劑和ARB、鹽皮質激素受體拮抗劑、利尿劑和其他心血管療法等主要藥物類別。

在這個市場運作的主要公司包括諾華公司、阿斯特捷利康公司、勃林格殷格翰國際有限公司、默克公司、安進公司、輝瑞公司、維亞特里斯公司、梯瓦製藥工業有限公司和山德士公司。

市場定義和範圍

心臟衰竭藥物是一種旨在改善心臟功能、降低住院風險、控制症狀和降低心臟衰竭患者心血管死亡率的藥物。

這些藥物用於治療各種類型的心臟衰竭，例如以下幾種：

  • 射血分數降低的心臟衰竭（HFrEF）
  • 射血分數保留型心臟衰竭（HFpEF）
  • 射血分數降低的輕度心臟衰竭（HFmrEF）
  • 急性補償心臟衰竭
  • 心肌梗塞後心臟衰竭

該市場包括透過醫院藥房、零售藥房、網路藥房和其他醫療保健管道分銷的品牌藥和學名藥藥。

市場動態

市場趨勢

SGLT2抑制劑的快速普及正在改變心臟衰竭。

SGLT2抑制劑的廣泛應用是影響心臟衰竭治療市場最重要的趨勢之一。這些藥物最初是為治療糖尿病而開發的，現在已廣泛用於治療射血分數降低型心臟衰竭（HFrEF）、射血分數保留型心臟衰竭（HFpEF）和射血分數中間值型心臟衰竭（HFmrEF）患者的心臟衰竭。

SGLT2抑制劑應用範圍的擴大，拓寬了其可治療的患者群體，從而提高了其銷售額。這一趨勢降低了對BETA阻斷劑、ACE抑制劑、ARB類藥物和利尿劑等傳統療法的依賴。

例如，2023 年 5 月，阿斯特捷利康的 Farxiga 獲得了美國食品藥物管理局)的批准，旨在降低心臟衰竭（無論左心室射血分數如何）因心臟衰竭導致的心血管死亡、住院和急診就診次數。

市場促進因素

心臟衰竭盛行率不斷上升和人口老化正在推動藥物需求的成長。

全球心臟衰竭負擔日益加重是推動市場擴張的主要動力。老年人口的成長、糖尿病、高血壓和肥胖症的盛行率上升，以及心血管事件後的存活率提高，都導致需要長期治療的患者人數增加。

隨著擴大採用基於指南的藥物療法，包括血管緊張素受體-腦啡肽酶抑制劑 (ARNI)、SGLT2 抑制劑、鹽皮質激素受體拮抗劑 (MRA)、血管緊張素轉換酶抑制劑 (ACEI)、血管緊張素受體阻斷劑 (ARB) 和BETA阻斷劑，品牌藥和學名藥的處方量都在增加。

醫療保健估計表明，美國約有 670 萬 20 歲及以上的成年人患有心臟衰竭，預計未來幾年這一數字將大幅增加，凸顯了治療需求的日益成長。

市場限制因素

昂貴的心臟衰竭藥物的保險報銷限制和獲取限制。

保險覆蓋範圍有限和經濟挑戰可能會限制市場成長，尤其是在中低收入國家。

雖然 ARNI 和 SGLT2 抑制劑等先進療法具有顯著的臨床益處，但由於高成本、保險覆蓋範圍有限以及專家短缺，它們在可及性方面常常面臨挑戰。

因此，一些新興市場仍依賴低成本的非專利心血管藥物。

市場機遇

擴大符合HFpEF和HFmrEF治療條件的患者群體

對 HFpEF 和 HFmrEF病患小組的日益關注帶來了巨大的成長機會。

傳統上，這些患者群體的治療選擇有限，但隨著 SGLT2 抑制劑在各種射血分數範圍內的日益普及，治療機會正在擴大。

診斷技術的改進、指南的廣泛採用以及臨床研究的增加預計將提高處方量，為參與企業創造新的商機。

市場挑戰

與SGLT2抑制劑相關的安全性和耐受性問題

SGLT2 抑制劑相關的安全問題可能會對更廣泛的應用構成挑戰，尤其是在老年患者、腎功能不全患者和高風險患者。

由於存在糖尿病酮酸症、體液容量不足和嚴重泌尿生殖道感染疾病等潛在風險，因此需要仔細監測和患者篩選。

即使臨床益處顯著，這些因素也可能減緩推廣速度。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 主要國家/地區主要疾病的流行情況
  • 產業重大發展動態（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 管道分析：按主要公司分類
  • 主要國家和地區監管和償還趨勢

第5章：2021-2034年全球心臟衰竭治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • SGLT2抑制劑
    • ARNI
    • BETA阻斷劑
    • ACE抑制劑與ARB
    • 鹽皮質激素受體拮抗劑
    • 利尿劑
    • 其他
  • 市場分析、洞察與預測：按指標
    • HFrEF
    • HFpEF
    • HFmrEF
    • 急性補償心臟衰竭
    • 心肌梗塞後心臟衰竭/左心室功能障礙（LV 功能障礙）
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 非專利的
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥局和藥房
    • 網路藥房
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美心臟衰竭治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲心臟衰竭治療市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區心臟衰竭治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章：拉丁美洲心臟衰竭治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第10章：2021-2034年中東和非洲心臟衰竭治療市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Novartis AG
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • Amgen Inc.
    • Pfizer Inc.
    • LEXICON PHARMACEUTICALS, INC.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz Inc.
Product Code: FBI118447

Growth Factors of heart failure drugs Market

The global heart failure drugs market size was valued at USD 11.79 billion in 2025. The market is projected to grow from USD 13.43 billion in 2026 to USD 38.46 billion by 2034, exhibiting a CAGR of 14.06% during the forecast period from 2026 to 2034. North America dominated the global heart failure drugs market in 2025 with a market share of 43.34%, reaching a valuation of approximately USD 5.11 billion.

The global heart failure drugs market includes prescription therapies used for the management of chronic and acute heart failure conditions across different indications. Market growth is driven by the rising global prevalence of heart failure, aging population, increasing cardiometabolic diseases such as diabetes and hypertension, wider adoption of guideline-directed medical therapy (GDMT), and increasing demand for advanced branded therapies.

The market includes major drug classes such as SGLT2 inhibitors, ARNI, beta blockers, ACE inhibitors & ARBs, mineralocorticoid receptor antagonists, diuretics, and other cardiovascular therapies.

Key players operating in the market include Novartis AG, AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Amgen Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., and Sandoz Inc.

Market Definition and Scope

Heart failure drugs are pharmaceutical products designed to improve heart function, reduce hospitalization risk, control symptoms, and decrease cardiovascular mortality among patients suffering from heart failure.

These medications are used across various heart failure categories, including:

  • Heart Failure with Reduced Ejection Fraction (HFrEF)
  • Heart Failure with Preserved Ejection Fraction (HFpEF)
  • Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)
  • Acute Decompensated Heart Failure
  • Post-Myocardial Infarction Heart Failure

The market covers branded and generic drugs distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other healthcare channels.

Market Dynamics

Market Trends

Rapid Adoption of SGLT2 Inhibitors Transforming Heart Failure Treatment

The increasing use of SGLT2 inhibitors is one of the most important trends shaping the heart failure drugs market. These medicines, initially developed for diabetes treatment, are now widely adopted for heart failure management across HFrEF, HFpEF, and HFmrEF patient groups.

The broader application of SGLT2 inhibitors is expanding the treated patient population and increasing their revenue contribution. This trend is reducing dependence on traditional therapies such as beta blockers, ACE inhibitors, ARBs, and diuretics.

For instance, in May 2023, AstraZeneca received U.S. FDA approval for Farxiga to reduce cardiovascular death, hospitalization, and urgent heart failure visits among adults with heart failure regardless of left ventricular ejection fraction status.

Market Drivers

Rising Heart Failure Prevalence and Aging Population Driving Drug Demand

The increasing global burden of heart failure is the major factor supporting market expansion. Growing elderly populations, rising cases of diabetes, hypertension, obesity, and improved survival after cardiovascular events are increasing the number of patients requiring long-term treatment.

The rising adoption of guideline-directed medical therapies, including ARNI, SGLT2 inhibitors, MRAs, ACE inhibitors, ARBs, and beta blockers, is increasing prescription volumes for both branded and generic drugs.

According to healthcare estimates, around 6.7 million adults aged 20 years and above in the U.S. have heart failure, and the number is expected to increase significantly in the coming years, highlighting the growing treatment requirement.

Market Restraints

Limited Reimbursement and Access to Premium Heart Failure Therapies

Limited reimbursement coverage and affordability challenges may restrict market growth, especially in low- and middle-income countries.

Advanced therapies such as ARNI and SGLT2 inhibitors provide significant clinical benefits but often face accessibility issues due to high costs, limited insurance coverage, and insufficient specialist availability.

As a result, several emerging markets continue to depend on lower-cost generic cardiovascular medicines.

Market Opportunities

Expansion of HFpEF and HFmrEF Treatment Pool

Increasing focus on HFpEF and HFmrEF patient groups is creating significant growth opportunities.

Historically, these patient populations had limited treatment options; however, increasing adoption of SGLT2 inhibitors across different ejection fraction ranges is expanding treatment opportunities.

Improved diagnosis, wider guideline adoption, and increasing clinical research are expected to increase prescription volumes and create new revenue opportunities for market participants.

Market Challenges

Safety and Tolerability Concerns Associated with SGLT2 Inhibitors

Safety concerns related to SGLT2 inhibitors may challenge broader adoption, particularly among elderly, renal-impaired, and high-risk patients.

Potential risks such as diabetic ketoacidosis, volume depletion, and serious genitourinary infections require careful monitoring and patient selection.

These factors may slow adoption despite strong clinical benefits.

Segmentation Analysis

By Drug Class

ARNI Segment Dominates Due to Strong Treatment Value

Based on drug class, the market is segmented into:

  • SGLT2 inhibitors
  • ARNI
  • Beta blockers
  • ACE inhibitors & ARBs
  • Mineralocorticoid receptor antagonists
  • Diuretics
  • Others

The ARNI segment dominated the market in 2025 due to the strong commercial performance of Entresto in chronic heart failure treatment.

High treatment value, strong clinical adoption, guideline recommendations, and recurring prescriptions supported segment leadership.

The SGLT2 inhibitors segment is expected to grow at a CAGR of 23.92% during 2026-2034, making it the fastest-growing drug class.

By Indication

HFrEF Segment Leads Due to Established Treatment Pathways

The HFrEF segment accounted for the largest market share in 2025 due to established treatment guidelines and extensive use of combination therapies.

The segment is expected to maintain approximately 57.6% share in 2026.

The HFpEF segment is projected to witness strong growth due to increasing availability of effective treatment options.

By Type

Branded Segment Holds Leading Market Position

The branded segment dominated the market in 2025 due to strong demand for high-value therapies such as Entresto, Farxiga, Jardiance, and other innovative treatments.

The segment is expected to hold approximately 68.1% share in 2026.

The generic segment is projected to grow at a CAGR of 12.47% during the forecast period due to increasing affordability and access.

By Route of Administration

Oral Segment Dominates Due to Long-Term Treatment Usage

The oral segment captured the largest share in 2025 due to widespread use of tablets and capsules for chronic heart failure management.

The segment is expected to hold approximately 93.9% share in 2026.

By Age Group

Adults Segment Dominates Due to Higher Disease Burden

The adults segment accounted for the largest market share in 2025 due to higher prevalence of heart failure among adult and elderly populations.

The segment is expected to maintain approximately 98.2% share in 2026.

By Distribution Channel

Retail Pharmacies and Drug Stores Lead Market

Retail pharmacies and drug stores dominated the market in 2025 due to recurring prescriptions and long-term outpatient treatment requirements.

The segment is expected to hold approximately 59.8% share in 2026.

Regional Insights

North America Heart Failure Drugs Market

North America dominated the global market in 2025 with a value of USD 5.11 billion.

Growth is supported by:

  • Strong healthcare infrastructure
  • High diagnosis rates
  • Better reimbursement coverage
  • Rapid adoption of branded therapies
  • Increasing use of SGLT2 inhibitors and ARNI therapies

U.S. Heart Failure Drugs Market

The U.S. market is estimated to reach approximately USD 5.34 billion in 2026, representing around 39.8% of global market revenue.

Europe Heart Failure Drugs Market

Europe is projected to grow at a CAGR of 13.02% during 2026-2034.

Growth is supported by increasing adoption of guideline-based treatment, aging population, and rising use of SGLT2 inhibitors.

Germany Heart Failure Drugs Market

Germany is expected to reach approximately USD 0.76 billion in 2026.

U.K. Heart Failure Drugs Market

The U.K. market is expected to reach approximately USD 0.61 billion in 2026.

Asia Pacific Heart Failure Drugs Market

Asia Pacific is expected to be the fastest-growing region due to increasing cardiovascular disease burden, rising healthcare expenditure, and improving access to advanced therapies.

The regional market is projected to reach USD 2.75 billion in 2026.

China Heart Failure Drugs Market

China is expected to reach approximately USD 0.91 billion in 2026.

Japan Heart Failure Drugs Market

Japan is expected to reach approximately USD 0.61 billion in 2026.

India Heart Failure Drugs Market

India is expected to reach approximately USD 0.33 billion in 2026.

Latin America and Middle East & Africa

Latin America is projected to reach USD 0.74 billion in 2026, supported by increasing cardiovascular disease burden and improving access to medications.

The GCC market is expected to reach approximately USD 0.25 billion in 2026 due to healthcare modernization and chronic disease management initiatives.

Competitive Landscape

Key Industry Players

The global heart failure drugs market is moderately consolidated, with leading companies focusing on innovative therapies, clinical research, geographic expansion, and strategic collaborations.

Major companies include:

  • Novartis AG
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • LEXICON Pharmaceuticals, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz Inc.

Companies are strengthening their market positions through branded drug development, generic launches, lifecycle expansion, and clinical evidence generation.

Key Industry Developments

  • January 2026: Viatris launched Inpefa/sotagliflozin in the UAE for heart failure treatment.
  • October 2025: Sandoz Canada launched generic sacubitril-valsartan to expand ARNI treatment access.
  • July 2025: Bayer received U.S. FDA approval for Kerendia in patients with heart failure and LVEF >=40%.
  • January 2025: Lupin received FDA approval for generic sacubitril and valsartan tablets.
  • August 2024: Bayer announced positive Phase III FINEARTS-HF trial results supporting future HF treatment expansion.

Report Coverage

The global heart failure drugs market report provides detailed analysis of market size, forecast, segmentation, regional performance, competitive landscape, product developments, regulatory environment, and emerging treatment trends.

The report evaluates key market drivers, restraints, opportunities, and challenges influencing market growth during the forecast period of 2026-2034.

Conclusion

The global heart failure drugs market is projected to grow from USD 11.79 billion in 2025 to USD 38.46 billion by 2034, driven by rising heart failure prevalence, aging populations, increasing adoption of guideline-directed medical therapies, and rapid expansion of SGLT2 inhibitors.

North America will continue to maintain market leadership due to advanced healthcare infrastructure, strong reimbursement systems, and high adoption of innovative therapies. Meanwhile, Asia Pacific is expected to witness significant growth due to increasing cardiovascular disease burden, improving healthcare access, and rising demand for advanced heart failure treatments.

Future market expansion will depend on continued innovation in cardiovascular therapies, improved affordability of premium drugs, wider adoption of personalized treatment approaches, and increased availability of advanced heart failure medicines across emerging economies.

Segmentation By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Region

By Drug Class

  • SGLT2 Inhibitors
  • ARNI
  • Beta Blockers
  • ACE Inhibitors & ARBs
  • Mineralocorticoid Receptor Antagonists
  • Diuretics
  • Others

By Indication

  • HFrEF
  • HFpEF
  • HFmrEF
  • Acute Decompensated Heart Failure
  • Post-MI Heart Failure / LV Dysfunction
  • Others

By Type

  • Branded
  • Generics

By Route of Administration

  • Oral
  • Parenteral

By Age Group

  • Adults
  • Pediatrics

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
  • Others

By Region

  • North America (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Region
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Regulatory & Reimbursement Scenario, By Key Countries/Region

5. Global Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. SGLT2 Inhibitors
    • 5.1.2. ARNI
    • 5.1.3. Beta Blockers
    • 5.1.4. ACE Inhibitors & ARBs
    • 5.1.5. Mineralocorticoid Receptor Antagonists
    • 5.1.6. Diuretics
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. HFrEF
    • 5.2.2. HFpEF
    • 5.2.3. HFmrEF
    • 5.2.4. Acute Decompensated Heart Failure
    • 5.2.5. Post-MI Heart Failure / LV Dysfunction
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generic
  • 5.5. Market Analysis, Insights and Forecast - By Age Group
    • 5.5.1. Pediatrics
    • 5.5.2. Adults
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Retail Pharmacies & Drug Stores
    • 5.6.3. Online Pharmacies
    • 5.6.4. Others
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. SGLT2 Inhibitors
    • 6.1.2. ARNI
    • 6.1.3. Beta Blockers
    • 6.1.4. ACE Inhibitors & ARBs
    • 6.1.5. Mineralocorticoid Receptor Antagonists
    • 6.1.6. Diuretics
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. HFrEF
    • 6.2.2. HFpEF
    • 6.2.3. HFmrEF
    • 6.2.4. Acute Decompensated Heart Failure
    • 6.2.5. Post-MI Heart Failure / LV Dysfunction
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generic
  • 6.5. Market Analysis, Insights and Forecast - By Age Group
    • 6.5.1. Pediatrics
    • 6.5.2. Adults
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies & Drug Stores
    • 6.6.3. Online Pharmacies
    • 6.6.4. Others
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. SGLT2 Inhibitors
    • 7.1.2. ARNI
    • 7.1.3. Beta Blockers
    • 7.1.4. ACE Inhibitors & ARBs
    • 7.1.5. Mineralocorticoid Receptor Antagonists
    • 7.1.6. Diuretics
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. HFrEF
    • 7.2.2. HFpEF
    • 7.2.3. HFmrEF
    • 7.2.4. Acute Decompensated Heart Failure
    • 7.2.5. Post-MI Heart Failure / LV Dysfunction
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generic
  • 7.5. Market Analysis, Insights and Forecast - By Age Group
    • 7.5.1. Pediatrics
    • 7.5.2. Adults
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies & Drug Stores
    • 7.6.3. Online Pharmacies
    • 7.6.4. Others
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. SGLT2 Inhibitors
    • 8.1.2. ARNI
    • 8.1.3. Beta Blockers
    • 8.1.4. ACE Inhibitors & ARBs
    • 8.1.5. Mineralocorticoid Receptor Antagonists
    • 8.1.6. Diuretics
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. HFrEF
    • 8.2.2. HFpEF
    • 8.2.3. HFmrEF
    • 8.2.4. Acute Decompensated Heart Failure
    • 8.2.5. Post-MI Heart Failure / LV Dysfunction
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generic
  • 8.5. Market Analysis, Insights and Forecast - By Age Group
    • 8.5.1. Pediatrics
    • 8.5.2. Adults
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies & Drug Stores
    • 8.6.3. Online Pharmacies
    • 8.6.4. Others
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Australia
    • 8.7.5. Southeast Asia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. SGLT2 Inhibitors
    • 9.1.2. ARNI
    • 9.1.3. Beta Blockers
    • 9.1.4. ACE Inhibitors & ARBs
    • 9.1.5. Mineralocorticoid Receptor Antagonists
    • 9.1.6. Diuretics
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. HFrEF
    • 9.2.2. HFpEF
    • 9.2.3. HFmrEF
    • 9.2.4. Acute Decompensated Heart Failure
    • 9.2.5. Post-MI Heart Failure / LV Dysfunction
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generic
  • 9.5. Market Analysis, Insights and Forecast - By Age Group
    • 9.5.1. Pediatrics
    • 9.5.2. Adults
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies & Drug Stores
    • 9.6.3. Online Pharmacies
    • 9.6.4. Others
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. SGLT2 Inhibitors
    • 10.1.2. ARNI
    • 10.1.3. Beta Blockers
    • 10.1.4. ACE Inhibitors & ARBs
    • 10.1.5. Mineralocorticoid Receptor Antagonists
    • 10.1.6. Diuretics
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. HFrEF
    • 10.2.2. HFpEF
    • 10.2.3. HFmrEF
    • 10.2.4. Acute Decompensated Heart Failure
    • 10.2.5. Post-MI Heart Failure / LV Dysfunction
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generic
  • 10.5. Market Analysis, Insights and Forecast - By Age Group
    • 10.5.1. Pediatrics
    • 10.5.2. Adults
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies & Drug Stores
    • 10.6.3. Online Pharmacies
    • 10.6.4. Others
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. AstraZeneca
    • 11.2.3. Boehringer Ingelheim International GmbH
    • 11.2.4. Merck & Co., Inc.
    • 11.2.5. Amgen Inc.
    • 11.2.6. Pfizer Inc.
    • 11.2.7. LEXICON PHARMACEUTICALS, INC.
    • 11.2.8. Viatris Inc.
    • 11.2.9. Teva Pharmaceutical Industries Ltd.
    • 11.2.10. Sandoz Inc.

List of Tables

  • Table 1: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 2: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 3: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 4: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034
  • Table 5: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 6: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 7: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Region, 2021-2034
  • Table 8: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 9: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 10: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 11: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034
  • Table 12: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 13: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 14: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 16: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 17: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 18: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034
  • Table 19: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 20: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 21: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 23: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 24: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 25: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034
  • Table 26: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 27: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 28: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 29: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 30: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 31: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 32: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034
  • Table 33: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 34: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 35: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034
  • Table 37: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 38: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 39: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034
  • Table 40: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 41: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Heart Failure Drugs Market Revenue Breakdown (USD Billion, %) By Region, 2025 & 2034
  • Figure 2: Global Heart Failure Drugs Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 3: Global Heart Failure Drugs Market Value Share (%), By Indication, 2025 & 2034
  • Figure 4: Global Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 5: Global Heart Failure Drugs Market Value Share (%), By Type, 2025 & 2034
  • Figure 6: Global Heart Failure Drugs Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 7: Global Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 8: Global Heart Failure Drugs Market Value Share (%), By Region, 2025 & 2034
  • Figure 9: North America Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034
  • Figure 10: North America Heart Failure Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 11: North America Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 12: North America Heart Failure Drugs Market Value Share (%), By Indication, 2025
  • Figure 13: North America Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034
  • Figure 14: North America Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 15: North America Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 16: North America Heart Failure Drugs Market Value Share (%), By Type, 2025
  • Figure 17: North America Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034
  • Figure 18: North America Heart Failure Drugs Market Value Share (%), By Age Group, 2025
  • Figure 19: North America Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034
  • Figure 20: North America Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 21: North America Heart Failure Drugs Market Value (USD Billion), by Country, 2025 & 2034
  • Figure 22: North America Heart Failure Drugs Market Value Share (%), by Country, 2025
  • Figure 23: Europe Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034
  • Figure 24: Europe Heart Failure Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 25: Europe Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 26: Europe Heart Failure Drugs Market Value Share (%), By Indication, 2025
  • Figure 27: Europe Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034
  • Figure 28: Europe Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 29: Europe Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 30: Europe Heart Failure Drugs Market Value Share (%), By Type, 2025
  • Figure 31: Europe Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034
  • Figure 32: Europe Heart Failure Drugs Market Value Share (%), By Age Group, 2025
  • Figure 33: Europe Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Europe Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Europe Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Heart Failure Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 39: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 40: Asia Pacific Heart Failure Drugs Market Value Share (%), By Indication, 2025
  • Figure 41: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034
  • Figure 42: Asia Pacific Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 43: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 44: Asia Pacific Heart Failure Drugs Market Value Share (%), By Type, 2025
  • Figure 45: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034
  • Figure 46: Asia Pacific Heart Failure Drugs Market Value Share (%), By Age Group, 2025
  • Figure 47: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 49: Asia Pacific Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034
  • Figure 52: Latin America Heart Failure Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 53: Latin America Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 54: Latin America Heart Failure Drugs Market Value Share (%), By Indication, 2025
  • Figure 55: Latin America Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034
  • Figure 56: Latin America Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 57: Latin America Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 58: Latin America Heart Failure Drugs Market Value Share (%), By Type, 2025
  • Figure 59: Latin America Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034
  • Figure 60: Latin America Heart Failure Drugs Market Value Share (%), By Age Group, 2025
  • Figure 61: Latin America Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 63: Latin America Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 67: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 68: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Indication, 2025
  • Figure 69: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034
  • Figure 70: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 71: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 72: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Type, 2025
  • Figure 73: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034
  • Figure 74: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Age Group, 2025
  • Figure 75: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 77: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Heart Failure Drugs Market Share (%), by Company, 2025